---
title: "Immix Biopharma, Inc. Q2 2026: Net loss $(11.56) M, EPS $(0.18) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295279091.md"
description: "Immix Biopharma reported a Q2 2026 net loss of $11.56M and diluted EPS of $(0.18), widening from the prior year's $6.62M loss, with no product revenue as it remains clinical-stage. The company completed enrollment in NEXICART-2, showing high response rates for NXC-201, which holds FDA Breakthrough Therapy and RMAT designations. Increased R&D spending supports Phase 3 efforts, funded by equity offerings and CIRM grants."
datetime: "2026-08-07T21:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295279091.md)
  - [en](https://longbridge.com/en/news/295279091.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295279091.md)
generator: "portal-rs"
---

# Immix Biopharma, Inc. Q2 2026: Net loss $(11.56) M, EPS $(0.18) — 10-Q Summary

Immix Biopharma, Inc. reported a larger consolidated net loss for the quarter ended June 30, 2026, with net income of $(11.56) M and diluted EPS of $(0.18); the company remains clinical-stage with no product revenue for the period.

**Financial Highlights**

-   Net income: $(11.56) M for the quarter ended June 30, 2026, versus $(6.62) M in the year-ago quarter.
-   Diluted EPS: $(0.18) for the quarter ended June 30, 2026, versus $(0.22) in the year-ago quarter.
-   Revenue: No product sales; company is clinical-stage and reports no revenue for the quarter.

**Business Highlights**

-   Clinical progress: Enrollment complete in NEXICART-2 (45 patients); Phase 1b/2 data show high complete response rates (95% of evaluable patients) and rapid responses.
-   Regulatory designations: NXC-201 received FDA Breakthrough Therapy, RMAT and orphan drug designations in the U.S. and EU, supporting an expedited development path.
-   R&D activity: Increased clinical R&D spending and higher CRO/site costs to support expanded trial operations and planned Phase 3 efforts.
-   Funding: Multiple equity offerings and CIRM grant reimbursements (~$8M) have funded trial progression and extended cash runway.
-   Safety profile: Favorable tolerability observed with no neurotoxicity and predominantly low-grade cytokine release syndrome, supporting broader development plans.

Original SEC Filing: Immix Biopharma, Inc. \[ IMMX \] - 10-Q - Aug. 07, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [IMMX.US](https://longbridge.com/en/quote/IMMX.US.md)

## Related News & Research

- [Immix Biopharma highlights NXC-201 CAR-T data in relapsed/refractory AL amyloidosis trial presentation](https://longbridge.com/en/news/297810101.md)
- [Apnimed, Inc. reports Q2 results](https://longbridge.com/en/news/298366495.md)
- [PHAT: Rapidly growing GI therapy targets $2B+ peak sales with expanding indications and strong physician adoption](https://longbridge.com/en/news/298481639.md)
- [Essex Property Trust declares Q3 2026 dividend of R$ 0.89 per unit](https://longbridge.com/en/news/298322539.md)
- [Braze, Inc. 2026: Revenue $227.23M, EPS ($0.17) — 10-Q Summary](https://longbridge.com/en/news/298436148.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**